301331 恩威医药
已收盘 11-22 15:00:00
资讯
新帖
简况
恩威医药（301331）股东成都瑞进恒企业管理有限公司质押341.08万股，占总股本3.32%
证券之星 · 11-15
恩威医药（301331）股东成都瑞进恒企业管理有限公司质押341.08万股，占总股本3.32%
恩威医药（301331）2024年三季报简析：净利润减69.81%
证券之星 · 10-25
恩威医药（301331）2024年三季报简析：净利润减69.81%
恩威医药(301331)9月30日股东户数0.65万户，较上期增加2.32%
证券之星 · 10-24
恩威医药(301331)9月30日股东户数0.65万户，较上期增加2.32%
恩威医药(301331.SZ)发布前三季度业绩，净利润2202万元，同比下降69.81%
智通财经 · 10-23
恩威医药(301331.SZ)发布前三季度业绩，净利润2202万元，同比下降69.81%
A股中药股异动拉升，香雪制药涨超10%，华森制药、粤万年青、恩威医药、维康药业等短线冲高。
美港电讯 · 10-15
A股中药股异动拉升，香雪制药涨超10%，华森制药、粤万年青、恩威医药、维康药业等短线冲高。
恩威医药(301331.SZ)累计回购3.0258%股份 耗资1.02亿元
智通财经 · 10-09
恩威医药(301331.SZ)累计回购3.0258%股份 耗资1.02亿元
中信证券股份有限公司关于恩威医药股份有限公司2024年半年度跟踪报告
证券日报 · 09-25
中信证券股份有限公司关于恩威医药股份有限公司2024年半年度跟踪报告
【机构调研记录】融通基金调研恩威医药
证券之星 · 09-24
【机构调研记录】融通基金调研恩威医药
恩威医药：融通基金、华源证券等多家机构于9月20日调研我司
证券之星 · 09-23
恩威医药：融通基金、华源证券等多家机构于9月20日调研我司
恩威医药(301331.SZ)累计回购3.0258%股份 耗资1.02亿元
智通财经 · 09-02
恩威医药(301331.SZ)累计回购3.0258%股份 耗资1.02亿元
恩威医药（301331）2024年中报简析：净利润减71.96%，三费占比上升明显
证券之星 · 08-31
恩威医药（301331）2024年中报简析：净利润减71.96%，三费占比上升明显
图解恩威医药中报：第二季度单季净利润同比减73.79%
证券之星 · 08-30
图解恩威医药中报：第二季度单季净利润同比减73.79%
恩威医药(301331.SZ)发布上半年业绩，净利润1793.44万元，下降71.96%
智通财经网 · 08-29
恩威医药(301331.SZ)发布上半年业绩，净利润1793.44万元，下降71.96%
恩威医药（301331）8月23日主力资金净卖出109.87万元
证券之星 · 08-26
恩威医药（301331）8月23日主力资金净卖出109.87万元
【恩威医药(301331.SZ)累计回购311.33万股 耗资1.02亿元】智通财经APP讯，恩威医药(301331.SZ)公告，公司截至2024年7月31日以集中竞价交易方式回购股份合计311.
智通财经 · 08-01
【恩威医药(301331.SZ)累计回购311.33万股 耗资1.02亿元】智通财经APP讯，恩威医药(301331.SZ)公告，公司截至2024年7月31日以集中竞价交易方式回购股份合计311.
恩威医药(301331.SZ)累计回购311.33万股 耗资1.02亿元
智通财经 · 08-01
恩威医药(301331.SZ)累计回购311.33万股 耗资1.02亿元
西藏板块盘中跳水，恩威医药跌1.29%
自选股智能写手 · 07-23
西藏板块盘中跳水，恩威医药跌1.29%
恩威医药(301331.SZ)已耗资1.02亿元回购3.03%股份
智通财经 · 07-19
恩威医药(301331.SZ)已耗资1.02亿元回购3.03%股份
【恩威医药(301331.SZ)已耗资1.02亿元回购3.03%股份】智通财经APP讯，恩威医药(301331.SZ)发布公告，截至2024年7月19日，公司已通过回购专用证券账户以集中竞价交易方式回购股份数量合计311.
智通财经 · 07-19
【恩威医药(301331.SZ)已耗资1.02亿元回购3.03%股份】智通财经APP讯，恩威医药(301331.SZ)发布公告，截至2024年7月19日，公司已通过回购专用证券账户以集中竞价交易方式回购股份数量合计311.
【恩威医药(301331.SZ)累计回购301.07万股 耗资9951.49万元】智通财经APP讯，恩威医药(301331.
智通财经 · 07-01
【恩威医药(301331.SZ)累计回购301.07万股 耗资9951.49万元】智通财经APP讯，恩威医药(301331.
暂无数据
公司概况
公司名称：
恩威医药股份有限公司
所属行业：
医药制造业
上市日期：
2022-09-21
主营业务：
恩威医药股份有限公司主营业务为中成药及化学药的研发、生产及销售。公司主要产品为妇科产品、儿科用药、呼吸系统用药等产品。公司在中国非处方药物协会主办的“2023健康中国-第二届中国OTC大会暨中国中医药促进大会”荣登“2023年度中国非处方药生产企业百强综合榜单”。
发行价格：
29.80
{"stockData":{"symbol":"301331","market":"SZ","secType":"STK","nameCN":"恩威医药","latestPrice":23.8,"timestamp":1732259019000,"preClose":25.17,"halted":0,"volume":1415134,"delay":0,"floatShares":31286200,"shares":103000000,"eps":0.3441,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.37,"latestTime":"11-22 15:00:00","open":25.41,"high":25.41,"low":23.75,"amount":34583500,"amplitude":0.066,"askPrice":23.8,"askSize":1,"bidPrice":23.79,"bidSize":24,"shortable":0,"etf":0,"ttmEps":0.3441,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":25.17,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":27.69,"lowLimit":22.65,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":102891887,"pbRate":2.53,"roa":"--","roe":"2.08%","epsLYR":1.2317,"committee":0.382716,"marketValue":2449000000,"floatMarketCap":745000000,"peRate":69.16594,"changeRate":-0.0544,"turnoverRate":0.0452,"status":1},"requestUrl":"/m/hq/s/301331/tweets","defaultTab":"tweets","newsList":[{"id":"2483371634","title":"恩威医药（301331）股东成都瑞进恒企业管理有限公司质押341.08万股，占总股本3.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371634","media":"证券之星","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483371634?lang=zh_cn&edition=full","pubTime":"2024-11-15 21:56","pubTimestamp":1731678973,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药11月15日公开信息显示，股东成都瑞进恒企业管理有限公司向国民信托有限公司合计质押341.08万股，占总股本3.32%。恩威医药主营业务：中成药及化学药的研发、生产及销售。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500045105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2478337697","title":"恩威医药（301331）2024年三季报简析：净利润减69.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478337697","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478337697?lang=zh_cn&edition=full","pubTime":"2024-10-25 06:10","pubTimestamp":1729807825,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩威医药发布2024年三季报。根据财报显示，恩威医药净利润减69.81%。截至本报告期末，公司营业总收入5.6亿元，同比下降1.67%，归母净利润2202.2万元，同比下降69.81%。按单季度数据看，第三季度营业总收入1.72亿元，同比下降1.4%，第三季度归母净利润408.75万元，同比下降54.45%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102500005412.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2477450695","title":"恩威医药(301331)9月30日股东户数0.65万户，较上期增加2.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477450695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477450695?lang=zh_cn&edition=full","pubTime":"2024-10-24 17:10","pubTimestamp":1729761051,"startTime":"0","endTime":"0","summary":"证券之星消息，近日恩威医药披露，截至2024年9月30日公司股东户数为6527.0户，较6月30日增加148.0户，增幅为2.32%。在中药行业个股中，恩威医药股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为4.94万户。从股价来看，2024年6月30日至2024年9月30日，恩威医药区间涨幅为24.69%，在此期间股东户数增加148.0户，增幅为2.32%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102400028664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2477584020","title":"恩威医药(301331.SZ)发布前三季度业绩，净利润2202万元，同比下降69.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477584020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477584020?lang=zh_cn&edition=full","pubTime":"2024-10-23 20:50","pubTimestamp":1729687830,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩威医药(301331.SZ)披露2024年第三季度报告，公司前三季度实现营收5.6亿元，同比下降1.67%;归母净利润2202万元，同比下降69.81%;扣非净利润2044万元，同比下降66.48%;基本每股收益0.2183元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1198372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301331"],"gpt_icon":0},{"id":"2475137421","title":"A股中药股异动拉升，香雪制药涨超10%，华森制药、粤万年青、恩威医药、维康药业等短线冲高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2475137421","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475137421?lang=zh_cn&edition=full","pubTime":"2024-10-15 11:13","pubTimestamp":1728962023,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300147","300878","399300","301331","BK0028","BK0070","BK0239","159982","002907","BK0060","301111"],"gpt_icon":0},{"id":"2474667211","title":"恩威医药(301331.SZ)累计回购3.0258%股份 耗资1.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474667211","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474667211?lang=zh_cn&edition=full","pubTime":"2024-10-09 17:37","pubTimestamp":1728466663,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩威医药(301331.SZ)公告，公司截至2024年9月30日以集中竞价交易方式回购股份数量合计311.33万股，占公司股份总数3.0258%，成交总金额为1.02亿元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1191756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2470410225","title":"中信证券股份有限公司关于恩威医药股份有限公司2024年半年度跟踪报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2470410225","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470410225?lang=zh_cn&edition=full","pubTime":"2024-09-25 01:59","pubTimestamp":1727200740,"startTime":"0","endTime":"0","summary":"一、保荐工作概述 二、保荐人发现公司存在的问题及采取的措施 三、公司及股东承诺事项履行情况 四、其他事项 保荐代表人：石 坡 叶建中 中信证券股份有限公司 2024年9月24日\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-09-25/doc-incqhuef4364453.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-09-25/doc-incqhuef4364453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997245094.SGD","BK1516","LU1720050803.USD","BK0012","BK1521","LU0405327148.USD","LU0405327494.USD","06030","BK0183","LU1064131003.USD","LU1064130708.USD","BK0188","LU1794554557.SGD","LU2289578879.USD","600030","LU2495084118.USD","LU2148510915.USD","301331","BK0239","BK0276","BK0196","BK1564","BK1147","BK0028","LU1997245177.USD","LU1997244956.HKD","LU1328615791.USD"],"gpt_icon":0},{"id":"2469210876","title":"【机构调研记录】融通基金调研恩威医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2469210876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469210876?lang=zh_cn&edition=full","pubTime":"2024-09-24 08:01","pubTimestamp":1727136107,"startTime":"0","endTime":"0","summary":"融通基金成立于2001年，截至目前，资产管理规模1503.98亿元，排名41/207；资产管理规模763.34亿元，排名56/207；管理公募基金数147只，排名45/207；旗下公募基金经理34人，排名33/207。旗下最近一年表现最佳的公募基金产品为融通中证精准医疗主题指数，最新单位净值为1.48，近一年增长60.11%。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092400005672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2469519385","title":"恩威医药：融通基金、华源证券等多家机构于9月20日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2469519385","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469519385?lang=zh_cn&edition=full","pubTime":"2024-09-23 17:34","pubTimestamp":1727084090,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年9月23日恩威医药发布公告称融通基金万民远、华源证券李强、华西基金李本刚于2024年9月20日调研我司。恩威医药主营业务：中成药及化学药的研发、生产及销售。融资融券数据显示该股近3个月融资净流出812.81万，融资余额减少；融券净流入3.5万，融券余额增加。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092300022581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331","BK0239","161027"],"gpt_icon":0},{"id":"2464880115","title":"恩威医药(301331.SZ)累计回购3.0258%股份 耗资1.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2464880115","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464880115?lang=zh_cn&edition=full","pubTime":"2024-09-02 18:55","pubTimestamp":1725274536,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩威医药(301331.SZ)公告，公司截至2024年8月31日以集中竞价交易方式回购股份数量合计311.33万股，占公司股份总数3.0258%，成交总金额为1.02亿元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1178233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2463166987","title":"恩威医药（301331）2024年中报简析：净利润减71.96%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2463166987","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463166987?lang=zh_cn&edition=full","pubTime":"2024-08-31 06:40","pubTimestamp":1725057631,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期恩威医药发布2024年中报。截至本报告期末，公司营业总收入3.88亿元，同比下降1.8%，归母净利润1793.44万元，同比下降71.96%。本报告期恩威医药三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达35.94%。去年的净利率为10.99%，算上全部成本后，公司产品或服务的附加值一般。财报体检工具显示：建议关注公司应收账款状况以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083100010036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2463629686","title":"图解恩威医药中报：第二季度单季净利润同比减73.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463629686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463629686?lang=zh_cn&edition=full","pubTime":"2024-08-30 02:12","pubTimestamp":1724955146,"startTime":"0","endTime":"0","summary":"证券之星消息，恩威医药2024年中报显示，公司主营收入3.88亿元，同比下降1.8%；归母净利润1793.44万元，同比下降71.96%；扣非净利润1517.45万元，同比下降71.57%；其中2024年第二季度，公司单季度主营收入2.05亿元，同比上升5.26%；单季度归母净利润951.05万元，同比下降73.79%；单季度扣非净利润849.43万元，同比下降69.21%；负债率31.11%，投资收益184.89万元，财务费用-36.39万元，毛利率51.87%。财报数据概要请见下图: 以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024083000003290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301331"],"gpt_icon":0},{"id":"2463259864","title":"恩威医药(301331.SZ)发布上半年业绩，净利润1793.44万元，下降71.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2463259864","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463259864?lang=zh_cn&edition=full","pubTime":"2024-08-29 21:16","pubTimestamp":1724937417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩威医药(301331.SZ)发布2024年半年度报告，报告期内，公司实现营业收入3.88亿元，同比下降1.80%。实现归属于上市公司股东的净利润1793.44万元，同比下降71.96%。实现归属于上市公司股东的扣除非经常性损益的净利润1517.45万元，同比下降71.57%。基本每股收益0.1769元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1175541.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["301331"],"gpt_icon":0},{"id":"2462737989","title":"恩威医药（301331）8月23日主力资金净卖出109.87万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2462737989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462737989?lang=zh_cn&edition=full","pubTime":"2024-08-26 09:20","pubTimestamp":1724635230,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年8月23日收盘，恩威医药报收于20.81元，下跌5.32%，换手率2.0%，成交量6628.0手，成交额1405.06万元。8月23日的资金流向数据方面，主力资金净流出109.87万元，占总成交额7.82%，游资资金净流出19.14万元，占总成交额1.36%，散户资金净流入129.01万元，占总成交额9.18%。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量4008.0股，融券余额8.34万元。恩威医药主营业务：中成药及化学药的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082600002401.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2456105762","title":"【恩威医药(301331.SZ)累计回购311.33万股 耗资1.02亿元】智通财经APP讯，恩威医药(301331.SZ)公告，公司截至2024年7月31日以集中竞价交易方式回购股份合计311.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456105762","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456105762?lang=zh_cn&edition=full","pubTime":"2024-08-01 17:55","pubTimestamp":1722506152,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2456057561","title":"恩威医药(301331.SZ)累计回购311.33万股 耗资1.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456057561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456057561?lang=zh_cn&edition=full","pubTime":"2024-08-01 17:55","pubTimestamp":1722506152,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩威医药(301331.SZ)公告，公司截至2024年7月31日以集中竞价交易方式回购股份合计311.33万股，占公司股份总数3.0258%，成交总金额为1.02亿元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1158821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301331","BK0239"],"gpt_icon":0},{"id":"2453708802","title":"西藏板块盘中跳水，恩威医药跌1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453708802","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453708802?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:11","pubTimestamp":1721715062,"startTime":"0","endTime":"0","summary":"07月23日，西藏板块盘中跳水，截至14点10分，西藏板块整体指数下跌2.02%，报1393.820点。从个股上来看，该板块的成分股中，恩威医药跌1.29%，易明医药、多瑞医药、卫信康跌幅居前。从资金上来看，截止发稿，西藏板块主力净流入为-2.54亿，其中卫信康受到资金热捧，主力净流入343.56万；拉长时间线来看，该板块近20日主力资金净流入-4.48亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723141102aefae8bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723141102aefae8bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["301331","603676","BK0239","BK0191"],"gpt_icon":0},{"id":"2452449926","title":"恩威医药(301331.SZ)已耗资1.02亿元回购3.03%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2452449926","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452449926?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:21","pubTimestamp":1721377289,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恩威医药(301331.SZ)发布公告，截至2024年7月19日，公司已通过回购专用证券账户以集中竞价交易方式回购股份数量合计311.33万股，占公司股份总数3.03%(以截至2024年7月18日公司总股本为基数计算)，最高成交价为44.78元/股，最低成交价为21.31元/股，成交总金额为1.02亿元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301331"],"gpt_icon":0},{"id":"2452444957","title":"【恩威医药(301331.SZ)已耗资1.02亿元回购3.03%股份】智通财经APP讯，恩威医药(301331.SZ)发布公告，截至2024年7月19日，公司已通过回购专用证券账户以集中竞价交易方式回购股份数量合计311.","url":"https://stock-news.laohu8.com/highlight/detail?id=2452444957","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452444957?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:21","pubTimestamp":1721377289,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["161027","301331","BK0239"],"gpt_icon":0},{"id":"2448960283","title":"【恩威医药(301331.SZ)累计回购301.07万股 耗资9951.49万元】智通财经APP讯，恩威医药(301331.","url":"https://stock-news.laohu8.com/highlight/detail?id=2448960283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448960283?lang=zh_cn&edition=full","pubTime":"2024-07-01 18:31","pubTimestamp":1719829899,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["301331","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-09-21","address":"西藏自治区昌都市卡若区经开区A坝区创业大道恩威大厦","stockEarnings":[{"period":"1week","weight":-0.0537},{"period":"1month","weight":-0.146},{"period":"3month","weight":0.1437},{"period":"6month","weight":-0.1103},{"period":"1year","weight":-0.2399},{"period":"ytd","weight":-0.1348}],"companyName":"恩威医药股份有限公司","boardCode":"AI0027","perCapita":"4793股","boardName":"医药制造业","registeredCapital":"10289万元","compareEarnings":[{"period":"1week","weight":-0.0191},{"period":"1month","weight":-0.0108},{"period":"3month","weight":0.1446},{"period":"6month","weight":0.0577},{"period":"1year","weight":0.0671},{"period":"ytd","weight":0.0982}],"survey":" 恩威医药股份有限公司主营业务为中成药及化学药的研发、生产及销售。公司主要产品为妇科产品、儿科用药、呼吸系统用药等产品。公司在中国非处方药物协会主办的“2023健康中国-第二届中国OTC大会暨中国中医药促进大会”荣登“2023年度中国非处方药生产企业百强综合榜单”。","serverTime":1732393253205,"listedPrice":29.8,"stockholders":"6527人(较上一季度增加2.32%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恩威医药,301331,恩威医药股票,恩威医药股票老虎,恩威医药股票老虎国际,恩威医药行情,恩威医药股票行情,恩威医药股价,恩威医药股市,恩威医药股票价格,恩威医药股票交易,恩威医药股票购买,恩威医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恩威医药(301331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恩威医药(301331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}